Recent News

• 02.09.2026 - Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment
• 02.05.2026 - Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
• 02.03.2026 - Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market
• 01.29.2026 - ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
• 01.21.2026 - Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders
• 01.08.2026 - Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

Recent Filings

• 02.06.2026 - EX-99.1 EX-99.1
• 02.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.03.2026 - EX-99.1 EX-99.1
• 02.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.29.2026 - EX-99.1 EX-99.1
• 01.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.21.2026 - EX-99.1 EX-99.1
• 01.21.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.16.2026 - 144 Report of proposed sale of securities